Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 4, 2011, Pages 407-415

  Dillman, Robert O ^a   Fogel, Gary B ^b   Cornforth, Andrew N ^a   Selvan, Senthamil R ^c   Schiltz, Patric M ^c   Depriest, Carol ^a  

^a Hoag Cancer Institute   (United States)

^b NATURAL SELECTION INC   (United States)

^c NATIONAL UNIVERSITY   (United States)

Author keywords

melanoma; multivariate analysis; vaccine

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; LACTATE DEHYDROGENASE;

ADULT; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CELL VIABILITY; CLINICAL LABORATORY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MALE; MELANOMA; PRIORITY JOURNAL; SKIN TEST;

CANCER VACCINES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LOGISTIC MODELS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80051734669     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.0973     Document Type: Article

References (26)

1. Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011;26:1.
2. Dillman RO, Selvan SR, Schlitz PM. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med 2006;355:1179.
3. Dillman RO, Selvan SR, Schiltz PM, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: Final Report. Cancer Biother Radiopharm 2009;24:311.
4. Balch CM, Gershenwald JE, Soong S-J, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199.
5. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205.
6. Schiltz PM, Dillman RO, Korse CM, et al. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells. Cancer Biother Radiopharm 2008;23:214.
7. Selvan SR, Dillman RO, Fowler AW, et al. Monitoring response to treatment in melanoma patients: Potential of a serum glycomic marker. Int J Cancer 2008;122:1374.
8. Cornforth AN, Lee GJ, Fowler AW, et al. Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. Clin Immunol 2009; 29:657.
9. Selvan SR, Carbonell DJ, Fowler AW, et al. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res 2010;20:280.
10. Cornforth AN, Fowler AW, Carbonell DJ, et al. Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Cancer Immunol Immunother 2011;60:123.
11. Lagakos SW. Statistical analysis of survival data. In: Bailar JC III, Mosteller F (eds.), Medical Uses of Statistics, 2nd edition. Boston: NEJM Books, 1992:281.
12. Fisher LD, Van Belle G. Association and prediction: Multiple regression analysis, linear models with multiple predictor variables. In: Fisher LD, Van Belle G (eds.), Biostatistics: A Methodology for the Health Sciences. New York: John Wiley and Sons, 1993:496.
13. Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527.
14. Brand CU, Ellwanger U, Stroebel W, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997;79:2345.
15. Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: A pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000;18:3782.
16. Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891.
17. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol 2005;17:167.
18. Linette GP, Carlson JA, Slominski A, et al. Biomarkers in melanoma: Stage III and IV disease. Expert Rev Mol Diagn 2005;5:65.
19. Prentice RL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989;8:431.
20. Fonseca C, Dranoff G. Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res 2008;14:1603.
21. Fry TJ, Shand JL, Milliron M, et al. Antigen loading of DCs with irradiated apoptotic tumor cells induces improved antitumor immunity compared to other approaches. Cancer Immunol Immunother 2009;58:1257.
22. Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol 2006;16:106.
23. Dillman RO, Beutel LD, Barth NM, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002;17:51.
24. Dillman RO, DeLeon C, Beutel LD, et al. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 2001;39:115.
25. Dillman RO, DePriest C, DeLeon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;22:309.
26. Dillman RO, Beutel LD, DePriest C, et al. Cancer vaccine potency: Is there a dose/response relationship for patientspecific vaccines and clinical outcomes? Cancer Biother Radiopharm 2005;20:373.